QUICK SPARK: Nvidia's Next Rally Could Create Another Fourteen Intels in Market Value
If Nvidia were to reach that level from its current price of around $226, its market capitalization would climb to about $12.5 trillion.
Read original at benzingaEconomy · News reference
Gold Jumps 4%, Dow Jones Smashes Record Highs: Stock Market Today
Gold posts its biggest one-day gain since February and the Dow sets a record as Iran deal hopes cool inflation fears.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
AMDAMGNANETAUGOCDWCRLCVSDIADTDVAEOGFRPTGDXGOOGLIWMLLYMDLNNEMNYTPBWPODDPRMBQQQRRXSPCXUBERVOOXLBXLCXLEXLUXLVXMEXOP
- Source
- benzinga
- Observed
- Aug 5, 2026, 6:14 PM
- Checked
- Aug 5, 2026, 6:14 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Why Is AMD Stock Trending Today?
AMD stock slipped in premarket trading as Nvidia's massive Q2 earnings beat drew focus, highlighting ongoing competition in data center AI hardware.
Read original at benzingaNvidia Stock Climbs Over 7% in Thursday Pre-Market: What’s Lifting Micron, Intel and Other Chip Stocks?
Nvidia shares surge 7.4% premarket as strong guidance boosts chip stocks, while CEO Jensen Huang cites robust AI demand.
Read original at benzingaCrowdStrike Posts Best Quarter Ever, but Cathie Wood's Ark Sells Shares Amid Cloudflare, Cerebras Buys
On Wednesday, Aug. 26, 2026, Ark Invest sold CrowdStrike and AMD shares after CrowdStrike's record quarter.
Read original at benzingaAstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophilic esophagitis (EoE) treatment.
Read original at benzingaAstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52Efficacy in a third epithelial-driven inflammatory disease supports broad potential of
Read original at benzinga